Clinical Study

Abt-C6-2017- A Randomized Phase I/II Open Label Study To Assess The Efficacy And Safety Of Abtl0812 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer At First Line Therapy

Posted Date: May 6, 2021

  • Investigator: Davendra Sohal
  • Specialties: Cancer, Oncology, Pancreatic Cancer
  • Type of Study: Drug

The main purpose of this study is to evaluate ABTL0812 in combination with gemcitabine and nab-paclitaxel as first line therapy in advanced pancreatic cancer. This will be evaluated by determining the number of emergent adverse events.


Patient Has Histologically Or Cytologically Confirmed Metastatic Adenocarcinoma Of The Pancreas, One Or More Metastatic Tumors, Ecog 0-1, Adequate Organ Function Per Protocol, Life Expectancy = 12 Weeks, No Symptomatic Brain Metastases, No Evidence Of Pre-Existing Uncontrolled Hypertension, No Hepatitis B Or C, No Medical Conditions That In The Opinion Of The Investigator May Interfere With The Planned Treatment, Affect Patient Compliance Or Place The Patient At High Risk From Treatment-Related Complications.


Pancreatic Cancer, Advanced

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.